Image Place holder

Scott J. Antonia, MD, PhD

Chair, Department of Thoracic Oncology

Specialty: Medical Oncology
Program: Thoracic Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Antonia is currently the Department Chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He is also a Professor of Oncologic Sciences at the University of South Florida College of Medicine in Tampa. Prior to being named chair of Thoracic Oncology in 2010, he was associate chairman of the Sarcoma Department. He joined the Moffitt Cancer Center in 1994. Dr. Antonia received his M.D. and his Ph.D. in Immunology from the University of Connecticut Health Center in Farmington, Connecticut. In addition, he completed an internal medicine residency at Yale University School of Medicine and pursued additional training at Yale through a medical oncology fellowship and post-doctoral fellowship in Immunobiology. Dr. Antonia’s work focuses on translational research. Using his molecular biology and cellular background in the development of immunotherapeutic strategies for the treatment of cancer patients, he has developed strategies designed to thwart the immunosuppressive mechanisms used by tumors to evade T-cell mediated rejection. His clinical interests focus on immunotherapy and immunobiology, in particular, gene-modified tumor cell vaccine trials at both pre-clinical and clinical stages. He has designed and conducted numerous cutting-edge studies with novel immunotherapeutics and has two patents for technology he has developed. He has been awarded a K24 grant from the National Cancer Institute to support his clinical research and is the principal investigator for a Thoracic SPORE project. Dr. Antonia is also conducting several ongoing investigator-initiated clinical trials testing novel tumor vaccines, and tumor vaccine augmentation strategies for the treatment of various cancers. Dr. Antonia also serves as chairman of Moffitt’s Scientific Review Committee and medical director of the Tumor Vaccine Production Facility at Moffitt. He was named the Moffitt Physician of the Year in 2005 and Mentor of the Year in 2008. Dr. Antonia has published papers in several peer-reviewed journals, including Science, Clinical Cancer Research, Current Opinions in Oncology, and Cancer Research. In 2014, he was recognized as the “Most Cited Faculty” during the Moffitt Faculty Appreciation/Recognition Reception. In 2015, he was inducted into the National Academy of Inventors.

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • Yale University of School of Medicine - Medical Oncology
  • Yale University of School of Medicine - Immunology

Residency:

  • Yale-New Haven Hospital - Internal Medicine

Medical School:

  • University of Connecticut Health Center - MD
Participating Trials

CLINICAL TRIAL 18393
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, or Squamous Cell Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: MGA271; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18928
A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma
Condition: Thoracic
Intervention: Alimta (Pemetrexed); BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Paraplatin (carboplatin); Pemetrexed; Yervoy (Ipilimumab); carboplatin; cisplatin
Open

CLINICAL TRIAL 18811
Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Condition: Thoracic
Intervention: ADI-PEG 20; Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Placebo; carboplatin; cisplatin
Open

CLINICAL TRIAL 19101
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); BMS-986205; Nivolumab
Open

CLINICAL TRIAL 17723
Expansion of Enduring Infrastructure to Support Lung Cancer Screening Research
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18431
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18558
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB00100718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies
Condition: Thoracic
Intervention: Avelumab; MSB00100718C (Avelumab); PD 0360324; PF-04518600; PF-05082566 (utomilumab)
Open

CLINICAL TRIAL 18611
The Gut Microbiome and Immunotherapy in Non-small Cell Lung Cancer
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18522
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: MAGE-A10c796T
Open

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable
Open

CLINICAL TRIAL 18197
A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); MM-121; Not Applicable; Pemetrexed; Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 17986
Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Condition: Multiple
Intervention: CP-675,206 (tremelimumab); KW-0761 (Mogamulizumab); MEDI4736 (Durvalumab); Mogamulizumab; Not Applicable; tremelimumab
Open

CLINICAL TRIAL 18342
A Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: G-CSF; MESNA; NY-ESO-1c259T; cyclophosphamide; cytoxan (cyclophosphamide)
Open

CLINICAL TRIAL 18398
Novartis Pharmaceuticals trial entitled: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Condition: Thoracic
Intervention: INC280 (Capmatinib)
Open

CLINICAL TRIAL 18094
A Phase 2 Study of Transarterial Chemoperfusion Treatment with Cisplatin, Methotrexate and Gemcitabine in Patients with Unresectable Pleural Mesothelioma
Condition: Thoracic
Intervention: Gemzar (gemcitabine); cisplatin; gemcitabine; methotrexate
Open

CLINICAL TRIAL 18321
Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
Condition: Thoracic
Intervention: PBF-509; PDR001
Open

CLINICAL TRIAL 18304
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Condition: Thoracic
Intervention: AZD1775; MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 18517
A Randomized, Open-Label, Active-Controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients with Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-Based Chemotherapy
Condition: Thoracic
Intervention: Anetumab Ravtansine (BAY 94-9343); Navelbine (Vinorelbine); Vinorelbine
Open

CLINICAL TRIAL 17908
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Condition: Thoracic
Intervention: 750009 (Rilotumumab); 765338 (AZD4547); 772256 (Palbociclib); AMG102 (Rilotumumab); AZD4547; BMN-673 (Talazoparib); BMS-936558 (Nivolumab); Dexamethasone; Erlotinib; GDC-0032 (Taselisib); Ipilimumab; MEDI4736 (Durvalumab); Nivolumab; Palbociclib; Rilotumumab; Talazoparib; Tarceva (Erlotinib); Taxotere (docetaxel); Yervoy (Ipilimumab); docetaxel
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 17970
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib; Placebo; Xalkori (Crizotinib)
Open

CLINICAL TRIAL 17969
Randomized Study of Erlotinib vs. Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Erlotinib; Not Applicable; Placebo; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 18915
A Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); MLN0128; Osimertinib; TAK-228 (MLN0128)
Open

CLINICAL TRIAL 18835
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)
Condition: Thoracic
Intervention: Adriamycin (doxorubicin); PM01183 (lurbinectedin); Topotecan; Vincristine; cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin
Open

CLINICAL TRIAL 17361
A Phase I/IB Trial of MEK162 in Combination with Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Condition: Thoracic
Intervention: Erlotinib; MEK162; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 18677
XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Condition: Thoracic
Intervention: Crizotinib; X-396 (Ensartinib); Xalkori (Crizotinib)
Open

CLINICAL TRIAL 18685
Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: X-396 (Ensartinib)
Open

CLINICAL TRIAL 18871
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18871
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18428
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Crizotinib; Erlotinib; Paraplatin (carboplatin); Tarceva (Erlotinib); Taxol (paclitaxel); Xalkori (Crizotinib); carboplatin; cisplatin; etoposide; paclitaxel
Open

CLINICAL TRIAL 18494
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 18561
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Condition: Multiple
Intervention: Not Applicable; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18909
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable
Open

CLINICAL TRIAL 18923
A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: BGB324; Erlotinib; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 17985
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Condition: Multiple
Intervention: INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18844
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Condition: Multiple
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19067
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 with Pembrolizumab in Adults with Previously-Treated Malignant Pleural Mesothelioma
Condition: Thoracic
Intervention: CRS-207; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18914
Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19083
A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); Daratumumab
Open

CLINICAL TRIAL 19082
A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 Sep;18(9):1261-1273. Pubmedid: 28729154.
  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Sep. Pubmedid: 28885881.
  • Yuan Z, Fromm A, Ahmed KA, Grass GD, Yang GQ, Oliver DE, Dilling TJ, Antonia SJ, Perez BA. Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung. J Thorac Oncol. 2017 Sep;12(9):e135-e136. Pubmedid: 28502722.
  • Ahmed KA, Grass GD, Creelan B, Gray J, Kim S, Dilling TJ, Antonia SJ, Perez BA. Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 May;98(1):224. Pubmedid: 28586976.
  • Tanvetyanon T, Gray JE, Antonia SJ. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. Expert Opin Biol Ther. 2017 Mar;17(3):305-312. Pubmedid: 28064556.
  • Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, Antonia SJ, Caudell JJ, Harrison LB, Sahebjam S, Gray JE, Etame AB, Johnstone PA, Yu M, Perez BA. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol. 2017 Jun;133(2):331-338. Pubmedid: 28466250.
  • John S, Antonia SJ, Rose TA, Seifert RP, Centeno BA, Wagner AS, Creelan BC. Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment. J Immunother Cancer. 2017 Jul;5(1):54. Pubmedid: 28716137. Pmcid: PMC5514517.
  • Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez DC, Stagg J, Antonia SJ. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia. 2017 Jul;19(7):530-536. Pubmedid: 28582704. Pmcid: PMC5458644.
  • Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE. A Bayesian pick-the-winner design in a randomized phase II clinical trial. Oncotarget. 2017 Jul. Pubmedid: 28706157.
  • Robinson LA, Jaing CJ, Campbell CP, Magliocco A, Xiong Y, Magliocco G, Thissen JB, Antonia S. Reply to: Comment on 'Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung'. Brit J Cancer. 2017 Jan;116(3):e6. Pubmedid: 27764846. Pmcid: PMC5294469.
  • Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18(1):31-41. Pubmedid: 27932067. Pmcid: PMC5476941.
  • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug;10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
  • Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2969-2979. Pubmedid: 27354481. Pmcid: PMC5569693.
  • Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2980-2987. Pubmedid: 27354485. Pmcid: PMC5569692.
  • Tanvetyanon T, Creelan BC, Antonia SJ. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. Expert Rev Anticancer Ther. 2016 Sep;16(9):903-910. Pubmedid: 27488231.
  • Borghaei H, Brahmer J, Horn L, Ready N, Steins M, Felip E, Paz-Ares L, Xx X, Barlesi F, Antonia S, Fayette J, Rizvi N, Crino L, Reck M, Erich Eberhardt WE, Hellmann M, Desai K, Li A, Healey D, Spigel D, Mathias C. P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy. J Thorac Oncol. 2016 Oct;11(10S):S237-S238. Pubmedid: 27676569.
  • Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, Hellmann MD. ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S):S250-S251. Pubmedid: 27969442.
  • Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S):S309-S310. Pubmedid: 27969529.
  • Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer. 2016 Mar;16:176. Pubmedid: 26935219. Pmcid: PMC4776434.
  • Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016 Mar;17(3):299-308. Pubmedid: 26858122. Pmcid: PMC5500167.
  • Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016 Jun;35(24):3209-3216. Pubmedid: 26477306. Pmcid: PMC4837098.
  • Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul;17(7):883-895. Pubmedid: 27269741.
  • Antonia SJ, Vansteenkiste JF, Moon E. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. Am Soc Clin Oncol Educ Book. 2016 Jul;35:e450-e458. Pubmedid: 27249753.
  • Raj S, Bui MM, Springett G, Conley A, Lavilla-Alonso S, Zhao X, Chen D, Haysek R, Gonzalez R, Letson GD, Finkelstein SE, Chiappori AA, Gabrilovitch DI, Antonia SJ. Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma. Sarcoma. 2016 Feb;2015:614736. Pubmedid: 26880867. Pmcid: PMC4735941.
  • Chen DT, Huang PY, Lin HY, Haura EB, Antonia SJ, Cress WD, Gray JE. Strategies for power calculations in predictive biomarker studies in survival data. Oncotarget. 2016 Dec;7(49):80373-80381. Pubmedid: 27661007. Pmcid: PMC5348326.
  • Antonia SJ. Moving beyond monotherapy in the immunotherapeutic arena: prospects for combination therapies in lung cancer. Clin Adv Hematol Oncol. 2016 Aug;14(8):616-618. Pubmedid: 27487105.
  • Robinson LA, Jaing CJ, Pierce Campbell C, Magliocco A, Xiong Y, Magliocco G, Thissen JB, Antonia S. Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. Brit J Cancer. 2016 Aug;115(4):497-504. Pubmedid: 27415011. Pmcid: PMC4985355.
  • Zheng H, Zhao W, Yan C, Watson CC, Messengill M, Xie M, Messengill C, Noyes D, Martinez GV, Afzal R, Chen Z, Ren X, Antonia SJ, Haura EB, Ruffell B, Beg AA. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2016 Aug;22(16):4119-4132. Pubmedid: 26964571. Pmcid: PMC4987196.
  • Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016 Apr;7(16):22928-22938. Pubmedid: 27008709. Pmcid: PMC5008412.
  • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct;373(17):1627-1639. Pubmedid: 26412456.
  • Appleyard CB, Antonia SJ, Sullivan DM, Santiago-Cardona PG, Cáceres W, Velez H, Torres-Ruiz JA, Wright KL. Building a long distance training program to enhance clinical cancer research capacity in Puerto Rico. Rev Recent Clin Trials. 2015 Mar;9(4):254-262. Pubmedid: 25626061. Pmcid: PMC4378863.
  • Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015 Mar;16(3):257-265. Pubmedid: 25704439.
  • Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jun;33(18):2004-2012. Pubmedid: 25897158. Pmcid: PMC4672027.
  • Haura EB, Beg AA, Rix U, Antonia S. Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies. Cancer Immunol Res. 2015 Jul;3(7):714-720. Pubmedid: 26081226. Pmcid: PMC4491034.
  • Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul;373(2):123-135. Pubmedid: 26028407. Pmcid: PMC4681400.
  • Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol. 2015 Jul;10(7):974-984. Pubmedid: 26134219. Pmcid: PMC4618296.
  • Tchekmedyian N, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia SJ. Propelling Immunotherapy Combinations Into the Clinic. Oncology (Williston Park). 2015 Dec;29(12):990-1002. Pubmedid: 26680224.
  • Soliman H, Mediavilla-Varela M, Antonia SJ. A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. Breast Cancer (Dove Med Press). 2015 Dec;7:389-397. Pubmedid: 26719725. Pmcid: PMC4687618.
  • Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014 Sep;5(18):8136-8146. Pubmedid: 25327557. Pmcid: PMC4226672.
  • Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct;5:5241. Pubmedid: 25348003. Pmcid: PMC4212319.
  • Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov;90(4):828-833. Pubmedid: 25216856.
  • Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014 Jun;124(6):2626-2639. Pubmedid: 24789911. Pmcid: PMC4038578.
  • Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One. 2014 Feb;9(2):e88557. Pubmedid: 24551119. Pmcid: PMC3925108.
  • Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res. 2014 Dec;20(24):6258-6268. Pubmedid: 25341541.
  • Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, Soliman H, Antonia S. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013 Sep;14(9):860-868. Pubmedid: 23917542. Pmcid: PMC3909555.
  • Gonzalez LE, Sutton SK, Pratt C, Gilbertson M, Antonia S, Quinn GP. The bottleneck effect in lung cancer clinical trials. J Cancer Educ. 2013 Sep;28(3):488-493. Pubmedid: 23733149. Pmcid: PMC4501775.
  • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct;36(8):442-450. Pubmedid: 23994887. Pmcid: PMC3846277.
  • Beg AA, Khan T, Antonia SJ. A new role for NFκB in immunosurveillance and its implications for cancer immunotherapy. Oncoimmunology. 2013 Oct;2(10):e25963. Pubmedid: 24404421. Pmcid: PMC3875605.
  • Pinder-Schenck MC, Antonia SJ. Adapting to the Brave New World of Lung Cancer Treatment. Oncology (Williston Park). 2013 May;27(5). Pubmedid: 25184264.
  • Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, Dorsey TH, Ambs S. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immun. 2013 May;62(5):829-837. Pubmedid: 23344392. Pmcid: PMC4501769.
  • Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immun. 2013 May;62(5):909-918. Pubmedid: 23589106. Pmcid: PMC3662237.
  • Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013 Mar;14(3):211-220. Pubmedid: 23354483. Pmcid: PMC3578019.
  • Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology. 2013 Mar;2(3):e23428. Pubmedid: 23802083. Pmcid: PMC3661168.
  • Hopewell EL, Zhao W, Fulp WJ, Bronk CC, Lopez AS, Massengill M, Antonia S, Celis E, Haura EB, Enkemann SA, Chen DT, Beg AA. Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest. 2013 Jun;123(6):2509-2522. Pubmedid: 23635779. Pmcid: PMC3668836.
  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
  • Creelan BC, Antonia SJ. Immunotherapy in lung cancer: "b7-bombers" and other new developments. Sem Resp Crit Care M. 2013 Dec;34(6):810-821. Pubmedid: 24258571.
  • Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May;118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.
  • Finkelstein SE, Fishman M, Conley AP, Gabrilovich D, Antonia S, Chiappori A. Cellular immunotherapy for soft tissue sarcomas. Immunotherapy. 2012 Mar;4(3):283-290. Pubmedid: 22401634. Pmcid: PMC4501768.
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun;366(26):2443-2454. Pubmedid: 22658127. Pmcid: PMC3544539.
  • Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys. 2012 Feb;82(2):924-932. Pubmedid: 21398051. Pmcid: PMC4241354.
  • McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012 Aug;25(4):477-485. Pubmedid: 22550162.
  • Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy. 2012 Apr;4(4):373-382. Pubmedid: 22512631. Pmcid: PMC4241355.
  • Mahmood ST, Agresta S, Vigil C, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011 Oct;129(8):1963-1969. Pubmedid: 21154746. Pmcid: PMC3776586.
  • Hunter TB, Manimala NJ, Luddy KA, Catlin T, Antonia SJ. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res. 2011 Oct;31(10):3193-3204. Pubmedid: 21965726. Pmcid: PMC4241353.
  • Riddle ND, Gonzalez RJ, Bridge JA, Antonia S, Bui MM. A CD117 and CD34 immunoreactive sarcoma masquerading as a gastrointestinal stromal tumor: diagnostic pitfalls of ancillary studies in sarcoma. Cancer Control. 2011 Jul;18(3):152-159. Pubmedid: 21666577.
  • Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010 Oct;33(8):817-827. Pubmedid: 20842055.
  • Rüter J, Antonia SJ, Burris HA, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010 Nov;10(10):983-993. Pubmedid: 20855968. Pmcid: PMC3047092.
  • Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010 Mar;16(6):1812-1823. Pubmedid: 20215551. Pmcid: PMC2840181.
  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
  • Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-991. Pubmedid: 20420527. Pmcid: PMC3146364.
  • Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft tissue sarcoma. J Natl Compr Canc Ne. 2010 Jun;8(6):630-674. Pubmedid: 20581298.
  • Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010 Aug;16(8):880-886. Pubmedid: 20622859. Pmcid: PMC2917488.
  • Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010 Apr;120(4):1111-1124. Pubmedid: 20234093. Pmcid: PMC2846048.
  • Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control. 2010 Apr;17(2):120-129. Pubmedid: 20404795.
  • Bui MM, Zheng Z, Antonia S, Bepler G. Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNET. Fetal Pediatr Pathol. 2010;29(6):385-392. Pubmedid: 21043562. Pmcid: PMC3568950.
  • Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar;27(7):1075-1081. Pubmedid: 19139427.
  • Ortega J, Hayes JM, Antonia S. Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. Cancer Chemother Pharmacol. 2009 Dec;65(1):187-190. Pubmedid: 19697030.
  • Ramakrishnan R, Antonia S, Gabrilovich D. Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother. 2008 Oct;57(10):1523-1529. Pubmedid: 18488219.
  • Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct;3(10):1112-1118. Pubmedid: 18827606. Pmcid: PMC2639211.
  • Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008 Nov;26(32):5198-5203. Pubmedid: 18824702. Pmcid: PMC4879696.
  • Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.
  • Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar;14(5):1464-1469. Pubmedid: 18316570.
  • Fishman M, Hunter T, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo M, Noyes D, Mahany J, Lee J, Cantor A, Messina J, Seigne J, Pow-Sang J, JanssenW, Antonia S. Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma. J Immunother (1997). 2008 Jan;31(1):72-80. Pubmedid: 18157014.
  • Hunter T, Alsarraj M, Gladue R, Bedian V, Antonia S. An Agonist Antibody Specific for CD40 Induces Dendritic Cell Maturation and Promotes Autologous Anti-tumour T-cell Responses in an In vitro Mixed Autologous Tumour Cell/Lymph Node Cell Model. Scand J Immunol. 2007 May;65(5):479-486. Pubmedid: 17444959.
  • Vonderheide R, Flaherty K, Khalil M, Stumacher M, Bajor D, Hutnick N, Sullivan P, Mahany J, Gallagher M, Kramer A, Green S, O'Dwyer P, Running K, Huhn R, Antonia S. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar;25(7):876-883. Pubmedid: 17327609.
  • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul;25(19):2741-2746. Pubmedid: 17602079.
  • Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia S. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol. 2007 Feb;14(2):869-884. Pubmedid: 17103257.
  • de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr;109(7):1413-1419. Pubmedid: 17326096.
  • Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006 Sep;66(18):9299-9307. Pubmedid: 16982775. Pmcid: PMC1586106.
  • Antonia S, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee J, Menander K, Chada S, Gabrilovich D. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006 Feb;12(3 Pt 1):878-887. Pubmedid: 16467102.
  • Simon G, Lush R, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan D, Munster P. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug;5(8):2130-2137. Pubmedid: 16928835.
  • Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM, Sandler AD. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg. 2006 Aug;41(8):1361-1368. Pubmedid: 16863838.
  • Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology-Basel. 2005 Sep;68(4-6):382-390. Pubmedid: 16020967.
  • Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia S. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res. 2005 May;125(2):173-181. Pubmedid: 15854671.
  • Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004 Jul;114(2):280-290. Pubmedid: 15254595. Pmcid: PMC449750.
  • Fishman M, Antonia S. Specific antitumour vaccine for renal cancer. Lancet. 2004 Feb;363(9409):583-584. Pubmedid: 14987879.
  • Rodriguez P, Quiceno D, Zabaleta J, Ortiz B, Zea A, Piazuelo M, Delgado A, Correa P, Brayer J, Sotomayor E, Antonia S, Ochoa J, Ochoa A. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004 Aug;64(16):5839-5849. Pubmedid: 15313928.
  • Antonia S, Mule J, Weber J. Current developments of immunotherapy in the clinic. Curr Opin Immunol. 2004;16(2):130-136. Pubmedid: 15023403.
  • Simon G, Ruckdeschel J, Williams C, Cantor A, Antonia S, Haura E, Rocha C, Chiappori A, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 2003 Sep;10(5):388-395. Pubmedid: 14581894.
  • Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. Mol Biotechnol. 2003 Oct;25(2):139-148. Pubmedid: 14526124.
  • Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest. 2003 Oct;83(10):1457-1466. Pubmedid: 14563947.
  • Fishman M, Antonia S. Novel therapies for renal cell carcinoma - an update. Expert Opin Investig Drugs. 2003;12(4):593-609. Pubmedid: 12665415.
  • Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. An introduction. Methods Mol Med. 2003;75:529-543. Pubmedid: 12407762.
  • Fishman M, Antonia S. Cell-based immune therapy for metastatic renal cancer. Expert Rev Anticancer Ther. 2003;3(6):837-849. Pubmedid: 14686706.
  • Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002 Sep;101(2):151-155. Pubmedid: 12209992.
  • Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL , Mellor AL. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002 Sep;297(5588):1867-1870. Pubmedid: 12228717.
  • Sotomayor MG, Yu H, Antonia S, Sotomayor EM, Pardoll DM. Advances in gene therapy for malignant melanoma. Cancer Control. 2002 Jan;9(1):39-48. Pubmedid: 11907465.
  • Antonia S, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo M, Friberg M, Alsarraj M, Mahany J, Pow-Sang J, Cantor A, Janssen W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002;167(5):1995-2000. Pubmedid: 11956426.
  • Fishman M, Seigne J, Antonia S. Novel therapies for renal cell carcinoma. Expert Opin Investig Drugs. 2001;10(6):1033-1044. Pubmedid: 11772233.
  • Antonia SJ, Sotomayor E. Gene therapy for lung cancer. Curr Opin Oncol. 2000 Mar;12(2):138-142. Pubmedid: 10750725.
  • Antonia S, Seigne J. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. World J Urol. 2000;18(2):157-163. Pubmedid: 10854153.
  • Jennings R, Munoz-Antonia T, Zhu Z, Jackson R, Antonia S. Identification of an enhancer element in the mouse B7-1 promoter. Immunogenetics. 1999 Oct;50(1-2):109-112. Pubmedid: 10541818.
  • Antonia S. Tumor cell vaccines for renal cell carcinoma. Cancer Control. 1999 Nov;6(6):608-611. Pubmedid: 10756394.
  • Jackson R, Antonia S, Wright K, Moon S, Nepvue A, Munoz-Antonia T. Human cut-like repressor protein binds TGFbeta type II receptor gene promoter. Arch Biochem Biophys. 1999 Nov;371(2):290-300. Pubmedid: 10545217.
  • Antonia S. B7-1 gene-modified tumor cell vaccines. Curr Opin Mol Ther. 1999 Feb;1(1):50-56. Pubmedid: 11249684.
  • Antonia S, Extermann M, Flavell R. Immunologic nonresponsiveness to tumors. Critical Rev Onco. 1998;9:35-41. Pubmedid: 9754446.
  • Antonia S, Ruckdeschel J. Improving our management of non-small-cell lung cancer and mesothelioma. Cancer Control. 1997;4(4):293-293. Pubmedid: 10763034.
  • Antonia S, Finley C, Munoz-Antonia T. Cloning and partial characterization of the mouse B7-1 promoter. Immunogenetics. 1996;43(4):234-237. Pubmedid: 8575824.
  • Rabb H, Ramirez G, Saba S, Reynolds D, Xu J, Flavell R, Antonia S. Renal ischemic-reperfusion injury in L-selectin-deficient mice. Am J Physiol. 1996;271:F408-F413. Pubmedid: 8770173.
  • Jackson R, Antonia S, Nepvue A, Munoz-Antonia T. A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression. Arch Biochem Biophys. 1996;56(21):4831-4835.
  • Munoz-Antonia T, Xiaochuan L, Reiss M, Rosalind J, Antonia S. A mutation in the transforming growth factor (beta) type II receptor gene promoter associated with loss of gene expression. Cancer Res. 1996;56:4831-4835. Pubmedid: 8895728.
  • Antonia S, Wagner, Jr. H, Williams, Jr. C, Alberts W, Hubbell D, Robinson L, Hilstro J, Ruckdeschel J. Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. Semin Oncol. 1995 Aug;22(4 Suppl 9):34-37. Pubmedid: 7644926.
  • Antonia S, Munoz-Antonia T, Soldevilla G, Miller J, Flavell R. B7-1 expression by a non-antigen presenting cell-derived tumor. Cancer Res. 1995;55:2253-2256. Pubmedid: 7538898.
  • Garrogue-Antar L, Munoz-Antonia T, Antonia S, Gesmond J, Vellucci V, Reiss M. Missense Mutations of the transforming growth factor (beta) type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 1995;55:3982-3987. Pubmedid: 7664267.
  • Antonia S, Geiger T, Miller J, Flavell R. Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein. Int Immunol. 1995;5:715-725. Pubmedid: 7547699.
  • Antonia SJ, Uchida J, Cohen S, Cohen MC. Attachment of tumor cells to endothelial monolayers: detection of surface molecules involved in cell-cell binding. Clin Immunol Immunopathol. 1989 Nov;53(2 Pt 1):281-296. Pubmedid: 2676274.
  • Antonia S, Robinson L, Ruckdeschel J, Wagner, Jr. H. Lung cancer treatment in the older patient. In: Balducci L, Lyman G, Ershler W, et al, eds. Comprehensive geriatric oncology. 2 ed. London. Harwood Academic Publishers; 1998;611-628.
  • Antonia S, Elliott E, Guerder S, Picarella D, Flavell R. Analysis of the immune system utilizing transgenesis and targeted mutagenesis. In: Bluethmann H, Ohashi P, eds. Studies of Tolerance, Inflammation, and Auto Immunity in Transgenic Mice. Academic Press; 1993.
  • Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor?. Cancer J. 16(4):354-359. Pubmedid: 20693847. Pmcid: PMC3850167.
  • Garland L, Ruckdeschel J, Wagner, Jr. H, Williams, Jr. C, Shaw G, Antonia S, Heise M, Hilstro J, Cantor A. Single agent paclitaxel as second-line chemotherapy for resistant, metastatic non-small cell lung cancer. In: Johnson, Klastersky, eds. Taxanes in Lung Cancer Therapy. New York, NY: Marcel Dekker; 1998;117-126.